MAPT and amyloidosis: The measurement of amyloidosis and tauopathy biomarkers in CSF (i.e., Aβ42/40 ratio, p-tau, and total tau (t-tau)) provides high diagnostic accuracy, even at the preclinical stage of AD [5].